© 2023 PCMA. All Rights Reserved.
Stop The Billion-Dollar Big Pharma Bailout
Before It’s Too Late
Big Pharma is the link between patients and high drug prices. And now they want a $32 BILLION bailout at the expense of patients, taxpayers and plan sponsors.
Big Pharma’s latest ‘delinking’ scheme would:
All while redistributing BILLIONS annually from Medicaid alone from patients back into Big Pharma’s pockets.
The Economics of “Delinking” PBM Compensation
“A significant share of these higher costs (an estimated $6.3 billion–$21.9 billion) would accrue to drug manufacturers.[…] Therefore, the aggregate effect of delinking in the commercial market and Part D could be an increase of more than $32 billion in drug profits.” ~Alex Brill
The Problem With Delinking In Drug-Price Negotiations
“Pharmacy benefit managers are one of the few mechanisms we have for constraining pharmaceutical prices. We should think carefully before taking steps to constrain them.”
The Truth About Big Pharma’s ‘Delinking’ Bailout:
Additional Information on Rx Drug Rebates
Regulating PBMs will not reduce drug costs – it will only help keep drug prices high. Don’t fall for Big Pharma’s ‘delinking’ blame game.
Rebates Unrelated to Higher Drug Prices